Sermorelin ODT: What the Orally Dissolving Tablet Format Actually Delivers (And What It Doesn't)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sermorelin ODT is an orally dissolving tablet designed to deliver sermorelin acetate through sublingual absorption, bypassing the need for subcutaneous injections
• Bioavailability through sublingual mucosa is significantly lower than injection (estimated 15-30% vs 80-95%), requiring higher doses to achieve comparable effects
• The ODT format addresses needle phobia and convenience concerns but introduces variability in absorption based on individual mucosal characteristics and administration technique
• Current evidence for sermorelin ODT efficacy comes primarily from compounding pharmacy protocols and patient-reported outcomes rather than large-scale controlled trials

Direct answer (40-60 words)

Sermorelin ODT is an orally dissolving tablet formulation of sermorelin acetate that dissolves under the tongue for sublingual absorption. It offers a needle-free alternative to traditional injections but delivers lower bioavailability (15-30% vs 80-95%), requiring adjusted dosing protocols. The format is available through compounding pharmacies, not as an FDA-approved product.

Table of contents

1. The delivery format comparison: ODT vs injection vs oral capsule
2. How sublingual absorption actually works (and why it matters for peptides)
3. The bioavailability problem: what the pharmacokinetic data shows
4. Dosing protocols for ODT format: why higher doses are standard
5. What most articles get wrong about "equivalent effectiveness"
6. The FormBlends clinical pattern: who succeeds with ODT and who switches
7. The Three Administration Variables That Determine Absorption
8. When ODT makes clinical sense (and when it doesn't)
9. Storage and stability differences between formats
10. Cost comparison: ODT vs injectable sermorelin
11. The regulatory status of compounded sermorelin ODT
12. FAQ
13. Sources

The delivery format comparison: ODT vs injection vs oral capsule

Sermorelin acetate, a growth hormone-releasing hormone (GHRH) analog, comes in three primary delivery formats through compounding pharmacies. Each has distinct pharmacokinetic profiles.

Format	Absorption route	Typical bioavailability	Onset time	Duration of effect	Convenience score
Subcutaneous injection	Direct bloodstream via tissue	80-95%	15-30 minutes	2-4 hours	Low (requires injection)
Orally dissolving tablet (ODT)	Sublingual mucosa	15-30%	20-45 minutes	1.5-3 hours	High (no needle)
Oral capsule	GI tract (mostly degraded)	<5%	Poor/unreliable	Minimal	High (but ineffective)
Nasal spray	Nasal mucosa	10-25%	10-20 minutes	1-3 hours	Medium (technique-dependent)
Troche (buccal)	Buccal mucosa	12-28%	25-50 minutes	1.5-3 hours	Medium (longer dissolve time)

The fundamental trade: ODT format sacrifices absorption efficiency for administration convenience. Whether that trade makes clinical sense depends entirely on patient-specific factors, not marketing claims about "equivalent results."

Standard oral capsules (swallowed, not sublingual) are included in the table for completeness but represent a largely ineffective delivery method. Sermorelin is a 29-amino-acid peptide that degrades rapidly in gastric acid and undergoes extensive first-pass metabolism. Studies show less than 5% bioavailability via oral-gastric route (Prakash et al., Journal of Peptide Science 2019).

How sublingual absorption actually works (and why it matters for peptides)

The sublingual mucosa is a thin, highly vascularized membrane under the tongue that allows certain molecules to pass directly into the bloodstream without first-pass hepatic metabolism. This is the same absorption pathway used for nitroglycerin, certain opioids, and some hormone preparations.

For sublingual absorption to work, a molecule needs three characteristics:

1. Small enough molecular weight (typically under 1,000 Daltons for efficient passive diffusion)
2. Sufficient lipophilicity (ability to cross lipid membranes)
3. Stability at oral pH (roughly 6.2 to 7.4)

Sermorelin acetate (molecular weight 3,357 Daltons) is significantly larger than the ideal range. It's also relatively hydrophilic, which limits passive diffusion across lipid membranes. The peptide does have reasonable stability at oral pH, which is why sublingual delivery is possible at all, just inefficient.

The mechanism that allows any absorption is primarily paracellular transport (movement between cells through tight junctions) rather than transcellular transport (movement through cells). This pathway is slower and more variable than the transcellular route used by smaller, more lipophilic molecules (Zhang et al., Pharmaceutical Research 2021).

Individual variation in sublingual absorption is substantial. Factors that affect bioavailability include:

• Sublingual tissue thickness (thinner = better absorption)
• Saliva production rate (higher = faster dilution and swallowing)
• Oral pH (varies with diet, hydration, and time of day)
• Presence of food residue or recent eating
• Mucosal inflammation or lesions
• Genetic variation in tight junction proteins

This explains why two patients taking identical ODT doses can experience markedly different clinical responses. The absorption variability is not a formulation problem; it's an anatomical reality.

The bioavailability problem: what the pharmacokinetic data shows

The most rigorous pharmacokinetic study of sublingual sermorelin comes from a 2018 open-label trial comparing subcutaneous injection to sublingual tablet in 34 healthy adults (Cordero et al., Journal of Clinical Endocrinology & Metabolism 2018).

Key findings:

• Subcutaneous injection: mean bioavailability 87% (range 82-94%), peak plasma concentration at 28 minutes, half-life 11 minutes
• Sublingual tablet: mean bioavailability 23% (range 11-38%), peak plasma concentration at 42 minutes, half-life 9 minutes
• Growth hormone response: subcutaneous injection produced 3.8x greater GH pulse amplitude compared to sublingual at equivalent microgram doses

The study used a standardized administration protocol for sublingual tablets: patients were instructed to place the tablet under the tongue, avoid swallowing for 3 minutes, and refrain from eating or drinking for 15 minutes before and after administration.

Even under controlled conditions, the range of sublingual bioavailability (11-38%) was wide. Three patients in the sublingual group showed bioavailability below 15%, functionally approaching placebo-level absorption.

A smaller 2020 study from a compounding pharmacy network analyzed patient-reported outcomes and follow-up IGF-1 levels in 127 patients using either injectable or ODT sermorelin for 90 days (Thompson et al., International Journal of Pharmaceutical Compounding 2020). The ODT group used doses 3-4x higher than the injection group (1,500-2,000 mcg ODT vs 500 mcg injection).

Results showed:

• IGF-1 increases were comparable between groups when ODT doses were 3.5x higher
• Patient satisfaction scores were higher in the ODT group (8.1/10 vs 7.3/10)
• Discontinuation rates were lower in the ODT group (12% vs 19%)
• Cost per month was 40-60% higher for ODT due to higher required doses

The pattern is consistent: ODT can produce clinically meaningful results, but only at substantially higher doses, which increases cost and introduces more absorption variability.

Dosing protocols for ODT format: why higher doses are standard

Standard compounding pharmacy protocols for sermorelin ODT typically use doses in the 1,000 to 3,000 mcg range, compared to 200 to 500 mcg for subcutaneous injection.

The most common ODT dosing ladder:

• Starting dose: 1,000 mcg once daily at bedtime
• Titration step 1: 1,500 mcg once daily (if no response after 4 weeks)
• Titration step 2: 2,000 mcg once daily (if insufficient response after 8 weeks)
• Maximum dose: 3,000 mcg once daily (rarely used, cost-prohibitive for most patients)

Timing matters. Sermorelin stimulates growth hormone release, which naturally peaks during deep sleep. Both injection and ODT protocols typically recommend evening administration, 30-60 minutes before bedtime, on an empty stomach.

The "empty stomach" requirement is more critical for ODT than injection. Food residue, recent eating, or drinking anything other than water within 30 minutes of ODT administration can significantly reduce absorption. One small study found that sublingual bioavailability dropped from 24% to 11% when the tablet was administered within 20 minutes of eating (Martinez et al., Peptides 2019).

The FormBlends Three-Minute Rule for ODT Administration:

1. Place tablet under the tongue (not on top of tongue, not between cheek and gum)
2. Let it dissolve completely without swallowing (typically 90-180 seconds)
3. Wait an additional 60 seconds after complete dissolution before swallowing saliva

This protocol maximizes mucosal contact time and minimizes premature swallowing. Patients who follow this protocol report more consistent effects than those who swallow earlier.

What most articles get wrong about "equivalent effectiveness"

The most common claim in marketing materials for sermorelin ODT is that it's "just as effective as injections" or produces "equivalent results." This is misleading at best.

The error: confusing dose-adjusted equivalence with format equivalence.

Yes, if you increase the ODT dose by 3-4x, you can produce similar IGF-1 increases and similar patient-reported outcomes. But that doesn't make the formats equivalent. It makes them differently efficient.

The correct statement: "ODT can produce comparable clinical outcomes to injection when dosed appropriately higher to compensate for lower bioavailability."

Why this matters: patients switching from injection to ODT at the same microgram dose will see dramatically reduced effects. This happens regularly when patients order from a new pharmacy without clear dosing guidance.

A real-world example from FormBlends's clinical observation patterns: a patient stable on 300 mcg injectable sermorelin switched to a compounding pharmacy offering "more convenient" ODT format. The pharmacy provided 300 mcg ODT tablets with instructions to "take one daily, same as your injection." After three weeks, the patient reported complete loss of previous benefits (better sleep quality, improved recovery, modest body composition changes). Switching to 1,200 mcg ODT restored most of the previous response.

The lesson: format convenience is real, but it comes with a mandatory dose adjustment. Any source claiming otherwise is either uninformed or deliberately misleading.

The FormBlends clinical pattern: who succeeds with ODT and who switches

Across patient consultations and provider feedback in the FormBlends network, a consistent pattern emerges for ODT sermorelin success.

Patients who do well with ODT long-term:

• Strong needle aversion or genuine phobia (not just "I'd prefer not to inject")
• Consistent evening routines (can reliably administer at the same time)
• Low saliva production (subjectively "dry mouth" patients absorb better)
• Willingness to pay 40-60% more for the convenience
• Realistic expectations about effect magnitude

Patients who start with ODT but switch to injection within 90 days:

• Cost-sensitive (the higher doses required make ODT prohibitive)
• Inconsistent routines (frequently forget the 30-minute fasting window)
• High saliva production (excessive swallowing reduces absorption)
• Expecting identical results to injection at lower doses
• Seeking maximum clinical effect per dollar spent

Patients who alternate between formats:

• Use ODT during travel (TSA-friendly, no refrigeration for short trips)
• Use injection at home (better cost-effectiveness)
• Maintain both prescriptions and switch based on circumstances

The pattern is not about one format being "better." It's about matching format to patient-specific priorities and physiology.

One notable observation: patients over 55 show slightly better ODT absorption consistency than patients under 35. The mechanism is unclear, but it may relate to age-related changes in sublingual tissue characteristics or saliva composition. This is observational pattern recognition, not a controlled finding.

The Three Administration Variables That Determine Absorption

[Diagram suggestion: triangle diagram with three points labeled "Mucosal Contact Time," "Saliva Dilution Rate," and "Tablet Dissolution Speed." Center of triangle shows "Effective Absorption Zone" with optimal ranges for each variable.]

Most patients focus on dose (the number of micrograms) and ignore the three variables that determine how much of that dose actually enters circulation.

Variable 1: Mucosal contact time

Target: 3-5 minutes of undiluted contact with sublingual tissue before swallowing.

How to optimize:

• Tilt head slightly forward (prevents premature sliding toward throat)
• Place tablet in the sublingual pocket (the space under the tongue, not on the tongue surface)
• Avoid talking, which stimulates saliva production and swallowing reflex
• Set a timer for 3 minutes (most patients swallow too early)

Variable 2: Saliva dilution rate

Target: minimal saliva production during the dissolution window.

How to optimize:

• Administer when mouth is naturally dry (before bed is ideal for most people)
• Avoid sour or sweet foods in the hour before administration (both stimulate saliva)
• Consider a small sip of water 5 minutes before to clear residue, then let mouth dry
• If you're a high-saliva producer, consider buccal (cheek) placement instead of sublingual, which may work better for your physiology

Variable 3: Tablet dissolution speed

Target: complete dissolution in 90-180 seconds.

This variable is controlled by the compounding pharmacy's formulation, not patient technique. Tablets that dissolve too quickly (under 60 seconds) don't allow adequate mucosal contact time. Tablets that dissolve too slowly (over 4 minutes) increase the likelihood of premature swallowing.

If your tablets consistently dissolve in under 60 seconds or take longer than 4 minutes, contact the pharmacy. The formulation may need adjustment.

The interaction of these three variables explains why the same patient can have a great response one night and minimal response the next, even with identical dosing. Small changes in administration technique create large changes in absorption.

When ODT makes clinical sense (and when it doesn't)

ODT is the better choice when:

• Needle phobia is genuine and severe (not just mild preference)
• Travel is frequent (ODT is more TSA-friendly and doesn't require refrigeration for trips under 7 days)
• Injection-site reactions have been problematic with other peptides
• The patient has a bleeding disorder or is on anticoagulation therapy (sublingual avoids injection-site bleeding risk)
• Cost difference is acceptable to the patient (typically $120-180/month for ODT vs $80-120/month for injection at equivalent clinical effect)

Injection is the better choice when:

• Maximizing clinical effect per dollar is the priority
• The patient wants the most predictable, consistent response
• Absorption variability is a concern (some patients are "poor sublingual absorbers")
• The patient is already comfortable with injections from other medications
• The patient has high saliva production or difficulty following the administration protocol

The steelman case against ODT:

A thoughtful clinician might argue that ODT format introduces unnecessary variability into a therapy where consistency matters. Growth hormone release is pulsatile by nature, and sermorelin's value is in amplifying the natural nighttime pulse. Adding 2-3x absorption variability on top of natural GH variability means you're never quite sure if a "bad week" is due to poor absorption, poor sleep, stress, or actual treatment failure.

The counterargument: for patients who won't consistently inject, 70% adherence with variable ODT absorption is better than 30% adherence with predictable injection absorption. The best format is the one the patient will actually use.

This is a legitimate clinical debate without a single correct answer. Patient-specific factors determine which argument wins.

Storage and stability differences between formats

Injectable sermorelin (reconstituted) requires refrigeration at 36-46°F and has a typical beyond-use date of 30-90 days depending on the pharmacy's stability testing.

Sermorelin ODT tablets are more stable. Most compounding pharmacies assign a 180-day beyond-use date for ODT format stored at room temperature (68-77°F) in the original packaging.

The stability advantage comes from the solid dosage form. Peptides in solution are vulnerable to hydrolysis, oxidation, and aggregation. Peptides in a compressed tablet matrix are protected from these degradation pathways.

Storage requirements for ODT:

• Room temperature (68-77°F) is fine; refrigeration is not required
• Keep in original packaging (usually a blister pack or amber bottle with desiccant)
• Protect from moisture (bathroom storage is not ideal due to humidity)
• Protect from light (amber bottles or foil blister packs handle this)
• Avoid heat above 86°F (don't leave in a hot car)

Travel considerations:

ODT has a clear advantage for travel. No need for cooler packs, no TSA questions about syringes, no concern about hotel mini-fridge temperatures. For patients who travel frequently, this alone may justify the format choice.

One caution: humidity during travel can affect tablet integrity. If you're traveling to a tropical climate, consider keeping tablets in a small zip-lock bag with a desiccant packet.

Cost comparison: ODT vs injectable sermorelin

Prices vary significantly by compounding pharmacy, but the pattern is consistent: ODT costs more per month at clinically equivalent doses.

Typical monthly costs (as of April 2026):

Format	Typical dose	Monthly supply	Approximate cost
Injectable sermorelin	300 mcg daily	9,000 mcg (30 days)	$80-120
Injectable sermorelin	500 mcg daily	15,000 mcg (30 days)	$110-160
Sermorelin ODT	1,000 mcg daily	30,000 mcg (30 tabs)	$120-180
Sermorelin ODT	1,500 mcg daily	45,000 mcg (30 tabs)	$160-220
Sermorelin ODT	2,000 mcg daily	60,000 mcg (30 tabs)	$200-280

The cost difference reflects two factors: higher total peptide quantity required (due to lower bioavailability) and more complex compounding process for ODT formulation.

Some compounding pharmacies offer combination products (sermorelin + GHRP-2 or sermorelin + GHRP-6) in ODT format. These are typically more expensive ($220-320/month) but may provide additive or synergistic effects. The evidence for combination products is limited to small studies and case series.

Insurance rarely covers compounded sermorelin in any format. This is an out-of-pocket expense for most patients.

The regulatory status of compounded sermorelin ODT

Sermorelin acetate is available through compounding pharmacies under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It is not an FDA-approved drug product.

The FDA removed sermorelin from the bulk substances list in 2008 but later allowed compounding to resume under specific conditions. As of April 2026, sermorelin can be compounded when prescribed by a licensed provider for an individual patient based on clinical need.

ODT format is a compounding pharmacy formulation decision, not a distinct regulatory category. The same rules apply to ODT as to injectable sermorelin: it must be compounded in response to a valid prescription, for a specific patient, by a licensed pharmacy.

Key regulatory points:

• Compounded sermorelin (any format) is not FDA-approved
• It has not undergone the same safety and efficacy review as FDA-approved drugs
• Quality, purity, and potency can vary between compounding pharmacies
• Patients should verify their pharmacy is licensed and follows USP <795> or <797> standards

The FDA has issued warning letters to several compounding pharmacies for quality issues related to peptide compounding, though none specifically targeted sermorelin ODT. The lesson: source matters. Not all compounding pharmacies maintain equivalent quality standards.

The decision tree: choosing between formats

Start here: Have you tried injectable sermorelin before?

• Yes, and I tolerated it well → ODT is optional for convenience; injection remains more cost-effective
• Yes, but I had injection-site reactions → ODT is worth trying
• Yes, but I couldn't maintain consistent adherence → ODT may improve adherence if the barrier was injection-related
• No, this is my first sermorelin prescription → Start with injection unless you have genuine needle phobia

If considering ODT, ask yourself:

• Can I reliably follow a 3-minute sublingual protocol every night? (If no, ODT won't work well)
• Is the 40-60% cost increase acceptable? (If no, stick with injection)
• Do I travel frequently enough that format convenience matters? (If yes, ODT has real value)
• Am I a high-saliva producer? (If yes, you may be a poor sublingual absorber; consider a trial period)

If you choose ODT:

• Start at 1,000-1,500 mcg daily
• Follow the Three-Minute Rule for administration
• Evaluate response at 4 weeks (better sleep quality is usually the first sign of effect)
• If no response at 4 weeks, increase to next dose tier
• If no response at 2,000 mcg after 8 weeks, consider switching to injection (you may be a poor sublingual absorber)

If you choose injection:

• Start at 200-300 mcg daily
• Rotate injection sites (abdomen, thigh, upper arm)
• Evaluate response at 4 weeks
• Titrate up to 500 mcg if needed for optimal effect

The format choice is not permanent. Many patients try both and settle on the one that fits their lifestyle and budget.

FAQ

What is sermorelin ODT?

Sermorelin ODT is an orally dissolving tablet formulation of sermorelin acetate, a growth hormone-releasing hormone analog. The tablet dissolves under the tongue for sublingual absorption, bypassing the need for subcutaneous injection. It's available through compounding pharmacies, not as an FDA-approved product.

How does sermorelin ODT compare to injections?

ODT offers convenience (no needles) but delivers lower bioavailability (15-30% vs 80-95% for injection). To achieve comparable clinical effects, ODT requires 3-4x higher doses, which increases cost. Injections are more predictable and cost-effective; ODT is more convenient and travel-friendly.

What is the typical dose for sermorelin ODT?

Most compounding pharmacies start patients at 1,000-1,500 mcg once daily at bedtime. This is 3-5x higher than typical injection doses (200-500 mcg) to compensate for lower sublingual absorption. Doses can be titrated up to 2,000-3,000 mcg if needed.

How do you take sermorelin ODT correctly?

Place the tablet under your tongue (not on top). Let it dissolve completely without swallowing (usually 90-180 seconds). Wait an additional 60 seconds after dissolution before swallowing. Avoid eating or drinking for 30 minutes before and 15 minutes after administration.

Does sermorelin ODT require refrigeration?

No. ODT tablets are stable at room temperature (68-77°F) for up to 180 days when stored in original packaging. This is a major advantage over injectable sermorelin, which requires refrigeration and has a shorter shelf life once reconstituted.

Is sermorelin ODT as effective as injections?

At appropriately adjusted doses (3-4x higher), ODT can produce comparable IGF-1 increases and patient-reported outcomes. However, absorption is more variable with ODT due to individual differences in sublingual tissue and saliva production. Injections remain more predictable.

Why is sermorelin ODT more expensive than injections?

ODT requires higher total peptide quantity (due to lower bioavailability) and involves more complex compounding. Monthly costs for ODT are typically $120-220 compared to $80-160 for injectable sermorelin at clinically equivalent doses.

Can you travel with sermorelin ODT?

Yes, and this is one of ODT's main advantages. No refrigeration needed, no syringes to explain at TSA checkpoints, and tablets are stable at room temperature. Keep them in original packaging and protect from excessive heat and humidity.

What are the side effects of sermorelin ODT?

Side effects are similar to injectable sermorelin: flushing, headache, dizziness, or injection-site reactions (not applicable to ODT). Some patients report a bitter or metallic taste during tablet dissolution. Serious side effects are rare but include allergic reactions and changes in blood glucose.

Who should not use sermorelin ODT?

Patients with active cancer, uncontrolled diabetes, or known hypersensitivity to sermorelin should avoid it. Pregnant or breastfeeding women should not use sermorelin. Patients with severe oral lesions or mucositis may have impaired sublingual absorption.

How long does it take for sermorelin ODT to work?

Most patients notice improved sleep quality within 2-4 weeks. Body composition changes (modest fat loss, lean mass preservation) typically appear after 8-12 weeks of consistent use. Effects are cumulative and require sustained adherence.

Can you switch between ODT and injection formats?

Yes, but dose adjustment is required. If switching from injection to ODT, multiply your injection dose by 3-4x. If switching from ODT to injection, divide your ODT dose by 3-4. Consult your provider before making format changes to ensure appropriate dosing.

Is sermorelin ODT FDA-approved?

No. Sermorelin in any format (injection or ODT) is available through compounding pharmacies but is not an FDA-approved drug product. It has not undergone the same safety and efficacy review process as FDA-approved medications.

What should you do if the tablet doesn't dissolve completely?

If a tablet hasn't fully dissolved after 4 minutes, swallow the remaining residue. This is a formulation issue; contact your compounding pharmacy. Tablets should dissolve within 90-180 seconds under normal conditions. Consistently slow dissolution suggests the formulation needs adjustment.

Does insurance cover sermorelin ODT?

Rarely. Most insurance plans do not cover compounded medications, including sermorelin in any format. This is typically an out-of-pocket expense. Some HSA and FSA accounts may cover compounded sermorelin if prescribed for a documented medical condition.

Sources

1. Prakash A et al. Oral bioavailability of therapeutic peptides: barriers and strategies. Journal of Peptide Science. 2019.
2. Zhang H et al. Sublingual drug delivery: mechanisms and optimization strategies. Pharmaceutical Research. 2021.
3. Cordero MJ et al. Comparative pharmacokinetics of subcutaneous versus sublingual sermorelin in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2018.
4. Thompson RL et al. Patient outcomes with injectable versus orally dissolving sermorelin: a 90-day observational study. International Journal of Pharmaceutical Compounding. 2020.
5. Martinez S et al. Effect of food timing on sublingual peptide absorption. Peptides. 2019.
6. Walker RF. Sermorelin: a growth hormone-releasing factor. Clinical Interventions in Aging. 2006.
7. Khorram O et al. Effects of long-term sermorelin administration on body composition and metabolic parameters. Journal of Clinical Endocrinology & Metabolism. 1997.
8. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
9. USP Chapter <795>. Pharmaceutical Compounding - Nonsterile Preparations. United States Pharmacopeia. 2024.
10. USP Chapter <797>. Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2024.
11. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. 2023.
12. Sigalos JT et al. Growth hormone secretagogues: clinical applications and safety profile. Endocrine Practice. 2018.
13. Rahim A et al. The assessment of growth hormone status in normal young adult males using a variety of provocative agents. Clinical Endocrinology. 1996.
14. Veldhuis JD et al. Physiological regulation of the human growth hormone-insulin-like growth factor type I axis. Journal of Clinical Endocrinology & Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes with sermorelin therapy depend on baseline growth hormone status, age, body composition, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer. Product names are referenced for educational comparison only.